Sarcopenia was previously used to describe deficiency of muscle mass. However, decrease in muscle strength is now the principal determinant of sarcopenia, instead of muscle mass [1]. This prompts a question of what the role of low muscle mass is. Given that direct measurement of muscle mass is technically difficult, lean mass, which is composed of primarily muscle mass, is the most commonly used surrogate of muscle mass.

In this special issue, we primarily evaluated the role of lean mass in mortality from different perspectives [2]. The robust association of lean mass with mortality suggests that it could be a predictor of mortality [3]. Yet, the accuracy of the prediction was not evaluated in the meta-analysis, as it was out of the scope of our study. Although we provide robust evidence on the association of lean mass with mortality, we did not independently assess the effect of muscle strength and function out of lean mass, as they are expected to be highly correlated. In our previous study using the data from the continuous NHANES [4], we stratified the population based on whether the study participants have normal gait speed and/or lean mass or not. We observed a consistent association with mortality in people with normal lean mass but slow gait speed. However, the association was inconsistent in people with normal gait speed but low lean mass. This is in line with the recent consensus that muscle strength overtakes the role of muscle mass as the principal determinant of sarcopenia [1,5,6]. Nevertheless, given that lean mass can be measured easily using digital scale with built-in bioelectrical impedance analysis (BIA) function, whether measuring lean mass alone is sufficient for assessment of sarcopenia is of clinical importance.

Loss of lean mass could be due to primary (age-related) and secondary causes (other than age-related cause). Lee et al [3] in this special issue showed that the association of low lean mass due to primary cause was significantly associated with increased risk of mortality. When compared with low lean mass due to secondary causes, the hazard ratio observed in the elderly population was the lowest when compared with the hazard ratio observed for other clinical conditions. This is not surprising, as low lean mass due to secondary causes could be a marker of disease progression and body catabolism, which are known to be associated with increased risk of mortality. As aforementioned, BIA is now commonly used even in the household digital scale. Thus, the usefulness of measuring lean mass using BIA is of public health significance.

Among all commonly used modalities in assessing lean mass, BIA was used as the least preferred. Li et al [7] in this special issue showed that BIA-measured lean mass was indeed robustly associated with mortality. This is a clear message showing that measuring...
lean mass using the BIA function in the digital scale could be a simple way in health monitoring.

Au et al [8] in this special issue, we examined the relationship between lean mass and cancer. Lean mass is again robustly associated with cancers. Notably, the number of studies included in the meta-analyses of several types of cancers was small, such as breast cancer (n = 1). Thus, no definite conclusion can be drawn. As this systematic review and meta-analysis searched for literature up to end of 2017, and many studies have been published since then, an updated meta-analysis will be important. Computed tomography (CT) is commonly used in cancer management, with lumbar L3 skeletal muscle index and psoas muscle commonly used to quantify muscle mass. However, the usefulness of psoas muscle has been controversial [1,9,10], since it is a small muscle, despite its high correlation with overall muscle mass [11]. Au et al [8] in this issue, we observed that both L3 skeletal muscle index and psoas muscle were both significantly associated with mortality. These observations provide further evidence on the validity of using psoas muscle to ascertain sarcopenia status.

Different cutpoints have been adopted in defining low lean mass for primary sarcopenia [1], but whether such cutpoints are useful in cancer-related sarcopenia is unclear. Thus, several cutpoints have been derived specifically for cancer-related sarcopenia, including the International Consensus of Cancer Cachexia [12,13], Martin [14], or Prado [15]. The relationship of different cancer-specific cutpoints with mortality were evaluated by Li et al [16] in this issue, and they showed a similar estimate. In summary, the meta-analyses included in this issue provide not only evidence on the relationship between low lean mass and mortality in different perspectives, but also propose several areas for further investigations.

Although the research community has been advocating the diagnosis and management of sarcopenia in clinical practice, multiple problems are still left to be solved. Examples include the perspectives investigated in the meta-analyses in this special issue, such as measurement modalities, site of measurement, cutoff points used in special population. These problems are indeed also present in the measurement of other sarcopenia components, such as grip strength. Grip strength would be affected by speed of twisting, use of dominant vs non-dominant hand, positioning of arms, and rest time between each test. Optimizing these factors could potentially enhance the predictive power of grip strength further. Moreover, to the best of our knowledge, we are the first group who derived an age-related loss of muscle strength (namely dynapenia) using a T-score that was derived from the normative data from the local Chinese population in Hong Kong [17,18], which is similar to the T-score calculation for bone mineral density. Given that grip strength is ethnic- and population-specific due to difference in genetics, diet, and lifestyle, deriving a population-specific T-score may be more accurate in reflecting the loss in muscle strength than using a specific cutoff point derived from a consensus based on studies from different ethnicities and populations. Nevertheless, in addition to performing studies such as dual-energy X-ray absorptiometry for measuring bone mineral density, a standard protocol in assessing sarcopenia is highly recommended.

In conclusion, this special issue provides not only a clearer picture about the role of lean mass in mortality, but also proposes several areas for further study. Development of a standard protocol in guiding measurement of sarcopenia related phenotypes is important. Such development requires further investigations. Regional and global collaborations are expected to facilitate the whole development process.

**CRediT author statement**

**Ching-Lung Cheung**: Conceptualization, Writing - Original Draft, Writing - Review & Editing. Supervision. **Gloria Hoi-Yee Li**: Writing - Original Draft, Writing - Review & Editing.

**Conflicts of interest**

All authors declare no competing interests.

**Acknowledgements**

**ORCID**

Ching-Lung Cheung: 0000-0002-6233-9144. Gloria Hoi-Yee Li: 0000-0003-0275-2356.

**References**

[1] Cruz-Jentoft AJ, Bahat G, Bauer J, Boirie Y, Bruyère O, Cederholm T, et al. Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing 2019;48:601.
[2] Cheung C-L, Lee GK-Y, Au PC-M, Li GH-Y, Chan M, Li H-L, et al. Systematic review and meta-analysis of lean mass and mortality: rationale and study description. Osteoporos Sarcopenia 2021;7(S1):S3–12.
[3] Lee GK-Y, Au PC-M, Li GH-Y, Chan M, Li H-L, Cheung BM-Y, et al. Sarcopenia and mortality in different clinical conditions: a meta-analysis. Osteoporos Sarcopenia 2021;7(S1):S19–27.
[4] Cheung CL, Lam KS, Cheung BM. Evaluation of cutpoints for low lean mass and slow gait speed in predicting death in the National Health and Nutrition Examination Survey 1999-2004. J Gerontol A Biol Sci Med Sci 2016;71:91–90.
[5] Schap LA, van Schoor NM, Lips P, Visser M. Associations of sarcopenia definitions, and their components, with the incidence of recurrent falling and fractures: the Longitudinal Aging Study Amsterdam. J Gerontol A Biol Sci Med Sci 2018;73:1199–204.
[6] Alley DE, Shardell MD, Peters KW, McLean RR, Dam TT, Kenny AM, et al. Grip strength cutpoints for the identification of clinically relevant weakness. J Gerontol A Biol Sci Med Sci 2014;69:S59–66.
[7] Li GH-Y, Lee GK-Y, Au PC-M, Chan M, Li H-L, Cheung BM-Y, et al. The effect of different measurement modalities in the association of lean mass with mortality: a meta-analysis. Osteoporos Sarcopenia 2021;7(S1):S13–8.
[8] Au PC-M, Li H-L, Lee GK-Y, Li GH-Y, Chan M, Cheung BM-Y, et al. Sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia 2021;7(S1):S28–33.
[9] Cesari M, Fielding RA, Pahor M, et al. Biomarkers of sarcopenia in clinical trials with recommendations from the international Working group on sarcopenia. J Cachexia Sarcopenia Muscle 2012;3:181–90.
[10] Hilmi M, Jouniot A, Burns R, Pigneur F, Mounier R, Gondin J, et al. Body composition and sarcopenia: the next-generation of personalized oncologic and pharmacology? Pharmacol Ther 2018:196:135–50.
[11] Jones KL, Doleman B, Scott S, Lund JN, Williams JP. Simple psoas cross-sectional area measurement is a quick and easy method to assess sarcopenia and predicts major surgical complications. Colorectal Dis 2015;17:020–06.
[12] Fearon K, Strasser F, Anker SD, et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 2011;12:489–95.
[13] Lustgarten MS, Fielding RA. Assessment of analytical methods used to measure changes in body composition in the elderly and recommendations for their use in phase II clinical trials. J Nutr Health Aging 2011;15:368–75.
[14] Martin L, Birdsell L, Macdonald N, Reiman T, Clendinnen MT, McCargar LJ, et al. Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol 2013;31:1539–47.
[15] Prado CM, Lieffers JR, McCargar LJ, Reiman T, Sawyer MB, Martin L, et al. Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol 2008;9:629–35.
[16] Li H-L, Au PC-M, Lee GK-Y, Li GH-Y, Chan M, Cheung BM-Y, et al. Different definition of sarcopenia and mortality in cancer: a meta-analysis. Osteoporos Sarcopenia 2021;7(S1):S34–8.
[17] Cheung CL, Nguyen US, Au E, Tan KC, Kung AW. Association of handgrip strength with chronic diseases and multimorbidity: a cross-sectional study. Age (Dordr) 2013;35:419–26.
[18] Cheung CL, Tan KC, Bow CH, Soong CS, Loong CH, Kung AW. Low handgrip strength is a predictor of osteoporotic fractures: cross-sectional and prospective evidence from the Hong Kong Osteoporosis Study. Age (Dordr) 2012;34:1239–46.